Program
Chimeric Antigen Receptor T-cells
Also written as “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, “CAR T cells” and “CAR-T cells”.
Its studies are mostly in Glioma · Lymphoma, Non-Hodgkin · Colorectal Neoplasms · Leukemia, Myeloid, Acute · Carcinoma, Hepatocellular, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tcelltech | 21 open or running | phase 1since Jun 15, 2024 | Jun 15, 2024 | none ahead |
| AGC Biologics | 10 open or running | phase 2since Aug 5, 2019 | Aug 5, 2019 | none ahead |
| Chongqing Precision Biotech | 11 open or running | phase 1since Jun 12, 2022 | Jun 12, 2022 | none ahead |
| Imunopharm Technology | 10 open or running | phase 1since Jan 27, 2021 | Jan 27, 2021 | none ahead |
| Shanghai Cell Therapy Group | 11 open or running | phase 1since Oct 11, 2021 | Oct 11, 2021 | none ahead |
| Shanghai GeneChem | 10 open or running | phase 2since Nov 6, 2016 | Nov 6, 2016 | none ahead |
| Suzhou Immunofoco Biotechnology | 11 open or running | phase 3since Jul 17, 2025 | Jul 17, 2025 | May 31, 2027phase 3 · NCT07103668 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 6, 2016First study: phase 2 study in Carcinoma, HepatocellularNew to Shanghai GeneChemShanghai GeneChem · NCT02959151 · 20 enrolled · China
- Aug 5, 2019AGC Biologics’ first study: phase 2 study in Leukemia, Myeloid, AcuteNew to AGC BiologicsAGC Biologics · NCT04097301 · 8 enrolled · Czechia, Italy
- Jan 27, 2021Imunopharm Technology’s first study: phase 1 study in AMLNew to Imunopharm TechnologyImunopharm Technology · NCT04766840 · 9 enrolled · China
- Oct 11, 2021Shanghai Cell Therapy Group’s first study: phase 1 study in Colorectal NeoplasmsNew to Shanghai Cell Therapy GroupShanghai Cell Therapy Group · NCT05089266 · 30 planned · China
- Jun 12, 2022Chongqing Precision Biotech’s first study: phase 1 study in Lymphoma, Non-HodgkinNew to Chongqing Precision BiotechChongqing Precision Biotech · NCT05420493 · 54 planned · China
- Jun 15, 2024Tcelltech’s first study: phase 1 study in GliomaNew to TcelltechTcelltech · NCT06482905 · 52 planned · United States, China
- Jul 17, 2025Suzhou Immunofoco Biotechnology’s first study: phase 3 study in Gastric AdenocarcinomaNew to Suzhou Immunofoco BiotechnologySuzhou Immunofoco Biotechnology · NCT07103668 · 150 planned · China
- Nov 13, 2025Phase 1 study in Solid TumorsTcelltech · NCT07231081 · 85 enrolled · China
Ahead
- May 31, 2027Primary completion: phase 3 study in Gastric AdenocarcinomaSuzhou Immunofoco Biotechnology · NCT07103668
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07231081Solid Tumors · China | 1 | Suspended | Tcelltech | Dec 20, 2027 | 85 |
| NCT07103668Gastric Adenocarcinoma · China | 3 | Recruiting | Suzhou Immunofoco Biotechnology | May 31, 2027 | 150 |
| NCT06482905Glioma · United States, China | 1 | Recruiting | Tcelltech | Sep 2026 | 52 |
| NCT05420493Lymphoma, Non-Hodgkin · China | 1 | Recruiting | Chongqing Precision Biotech | Sep 30, 2024 | 54 |
| NCT05089266Colorectal Neoplasms · China | 1 | Recruiting | Shanghai Cell Therapy Group | Jul 30, 2024 | 30 |
| NCT04766840AML · China | 1 | UNKNOWN | Imunopharm Technology | Jun 1, 2023 | 9 |
| NCT04097301Leukemia, Myeloid, Acute · Czechia, Italy | 2 | Terminated | AGC Biologics | Jun 18, 2021 | 8 |
| NCT02959151Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Shanghai GeneChem | Jan 2018 | 20 |
How it is read
Names in the registry
- “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, 2 entries
- “CAR T cells”, 2 entries
- “CAR-T cells”, 2 entries
- “MLM-CAR44.1 T-cells at day 0 Single intravenous infusion”, 1 entry
- “CAR-T cell”, 1 entry
Conditions, from the studies’ own filings
- Glioma, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Colorectal Neoplasms, 1 study
- Leukemia, Myeloid, Acute, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.